The Latest Breaking News from Perrigo

U.S. health regulators are weighing the first-ever request to make a birth control pill available without a prescription

U.S. regulators will hold a joint meeting in May to review whether Perrigo Co.’s birth-control product Opill can be sold without a prescription.

Upgrades

The Dow Jones Industrial Average fell Tuesday ahead of Wednesday's key inflation report. Vaccine maker Novavax crashed on earnings results.

A Relative Strength Rating upgrade for Perrigo stock shows improving technical performance.

The ruling by the U.S. Supreme Court to overturn Roe v. Wade and leave the decision of abortion to the states has been a big topic over the last few days. An analyst singles out a pharmaceutical company that could benefit from increased purchases of over-the-counter contraceptives.

While shortages have tormented parents, baby formula makers are recording higher profit margins.

The shares of leading baby formula maker Perrigo Company (PRGO) have been soaring in price of late amid a nationwide baby formula shortage. So, because the crisis is expected to continue through the coming months, will PRGO be able to maintain this momentum in the near term? Read more to…

Perrigo Company plc's (NYSE: PRGO) Q1 FY22 sales increased 6.4% Y/Y to $1.07 billion, almost in line with the consensus of $1.1 billion. The growth was led by strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. after competitor recall. Adjusted EPS decreased 34% to $0.33, as higher sales…